Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk–benefit

Imagine a medicine that is expected to have very limited effects based upon knowledge of its pharmacology and (patho)physiology and that is studied in the wrong population, with low-quality studies that use a surrogate end-point that relates to the clinical end-point in a partial manner at most. Suc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Heuberger, Jules A A C, Cohen Tervaert, Joost M, Schepers, Femke M L, Vliegenthart, Adriaan D B, Rotmans, Joris I, Daniels, Johannes M A, Burggraaf, Jacobus, Cohen, Adam F
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Science Inc 2013
Assuntos:
Reviews
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3690100/
https://ncbi.nlm.nih.gov/pubmed/23216370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12034
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares